Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -27.25% is 24% above its 5-year average of -35.65%, near the high end of its 5-year range (-60.36%–-23.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.72% above its 12-month average of -41.74%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -27.25%.
RETURN ON INVESTED CAPITAL (ROIC)
-27.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-41.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-42.42%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-35.65%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-66.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-61.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-68.02%
CURRENT VS TTM AVG
+34.72%
CURRENT VS 3Y AVG
+35.77%
CURRENT VS 5Y AVG
+23.58%
CURRENT VS 10Y AVG
+58.77%
CURRENT VS 15Y AVG
+55.74%
CURRENT VS 20Y AVG
+59.94%
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+23.56%
vs the sector median at left
Anavex Life Sciences Corp.
Market Cap
$145.96M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-41.74%
3Y Avg
-42.42%
5Y Avg
-35.65%
Market Cap
$146.01M
Return on Invested Capital (ROIC)
-134.15%
TTM Avg
-47.87%
3Y Avg
-96.96%
5Y Avg
-96.99%
Market Cap
$145.33M
Return on Invested Capital (ROIC)
-47.18%
TTM Avg
-30.67%
3Y Avg
-45.90%
5Y Avg
-38.17%
Market Cap
$147.13M
Return on Invested Capital (ROIC)
-64.72%
TTM Avg
-41.34%
3Y Avg
-24.79%
5Y Avg
-23.17%
Market Cap
$145.89M
Return on Invested Capital (ROIC)
-223.90%
TTM Avg
-825.42%
3Y Avg
-606.12%
5Y Avg
-416.73%
Market Cap
$146.82M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$146.62M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$146.67M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$144.06M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $145.96M | -27.25% | -41.74% | -42.42% | -35.65% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.01M | -134.15% | -47.87% | -96.96% | -96.99% |
| Protara Therapeutics, Inc. (TARA)vs › | $145.33M | -47.18% | -30.67% | -45.90% | -38.17% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | -64.72% | -41.34% | -24.79% | -23.17% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $145.89M | -223.90% | -825.42% | -606.12% | -416.73% |
| Codexis, Inc. (CDXS)vs › | $146.82M | -23.41% | -38.99% | -40.72% | -30.95% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -118.67% | -87.91% | -55.09% | -41.64% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $146.67M | -56.53% | -185.89% | -125.01% | -88.85% |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | -10.85% | -101.00% | -120.85% | -96.47% |
| Nyxoah S.A. (NYXH)vs › | $142.60M | -61.13% | -65.92% | -49.38% | -37.06% |
ROIC
-27.2%
ROE
-21.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -27.25% |
| 2026-03-31 | -31.69% |
| 2025-12-31 | -35.22% |
| 2025-09-30 | -54.19% |
| 2025-06-30 | -60.36% |
| 2025-03-31 | -55.18% |
| 2024-12-31 | -49.73% |
| 2024-09-30 | -44.02% |
| 2024-06-30 | -39.50% |
| 2024-03-31 | -37.12% |
| 2023-12-31 | -38.17% |
| 2023-09-30 | -39.29% |
| 2023-06-30 | -39.77% |
| 2023-03-31 | -39.47% |
| 2022-12-31 | -40.42% |
| 2022-09-30 | -35.78% |
| 2022-06-30 | -31.81% |
| 2022-03-31 | -30.78% |
| 2021-12-31 | -30.25% |
| 2021-09-30 | -27.81% |
| 2021-06-30 | -23.67% |
| 2021-03-31 | -44.79% |
| 2020-12-31 | -70.64% |
| 2020-09-30 | -113.59% |
| 2020-06-30 | -120.34% |
| 2020-03-31 | -115.63% |
| 2019-12-31 | -111.84% |
| 2019-09-30 | -141.98% |
| 2019-06-30 | -160.80% |
| 2019-03-31 | -182.12% |
| 2018-12-31 | -130.61% |
| 2018-09-30 | -93.62% |
| 2018-06-30 | -78.64% |
| 2018-03-31 | -78.48% |
| 2017-12-31 | -64.58% |
| 2017-09-30 | -64.07% |
| 2017-06-30 | -72.13% |
| 2017-03-31 | -72.26% |
| 2016-12-31 | -73.45% |
| 2016-09-30 | -235.83% |
| 2016-06-30 | -158.37% |
| 2016-03-31 | -118.25% |
| 2015-12-31 | -88.65% |
| 2015-09-30 | -55.13% |
| 2015-06-30 | -53.01% |
| 2015-03-31 | -66.32% |
| 2014-12-31 | -59.85% |
| 2014-09-30 | -48.64% |
| 2014-06-30 | -49.87% |
| 2014-03-31 | -33.97% |
| 2006-09-30 | -570.10% |
| 2006-06-30 | -600.27% |
